Key Takeaways Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns.On ...

Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome issues. Click for more on BLCO and BHC.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. The medical ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade the company's valuation. Learn more on BHC stock here.

Social Media Initiative Includes Donation to Prevent Blindness' Sight-Saving Fund BRIDGEWATER, N.J. and CHICAGO, Feb. 1, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of ...

The company maintained its guidance for 2022, saying it expects full-year revenue of $3.75 billion to $3.80 billion. Bausch went public earlier this year. It is still 90% owned by Bausch Health Cos. .

LAVAL, QC, Oct. 6, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that three poster ...

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb chairman and CEO Brent Saunders won't be making in 2025. The one for his contact lens ...

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

Vision Care Segment 3. Vision Care segment revenues were $587 million for the first quarter of 2023, as compared to $560 million for the first quarter of 2022, an increase of $27 million, or 5%.

Bausch + Lomb Corp. Follow. 1 results. April 11, 2024. Bausch wins US appeal to block Alvogen generic of diarrhea drug. A U.S. appeals court on Thursday affirmed a decision for Bausch Health that ...